Gene · 4985
OPRD1: opioid receptor delta 1
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. OPRD1: opioid receptor delta 1. Genes, record 4985. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/4985
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P41143 | Delta-type opioid receptor | 372 | 18 | Ensembl, GeneID, HGNC |
Source UniProt
Patents32
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 56537 | P41143 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 2950 | P41143 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 2950 | P41143 | Espacenet |
| JP 2025032204 A | 2025-03-11 | 32785 | P41143 | Espacenet |
| EP 4461818 A2 | 2024-11-13 | 32785 | P41143 | Espacenet |
| JP 2023058610 A | 2023-04-25 | 32785 | P41143 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 60151 | P41143 | Espacenet |
| US 11400116 B2 | 2022-08-02 | 324 | P41143 | Espacenet |
| US 11352422 B2 | 2022-06-07 | 54 | P41143 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 163122 | P41143 | Espacenet |
1 to 10 of 32
See all 32 patentsDrugs30
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| ADL-5747 | CHEMBL4297345 | Delta opioid receptor agonist | AGONIST | ChEMBL |
| ADL-5747 FREE BASE | CHEMBL561339 | Delta opioid receptor agonist | AGONIST | ChEMBL |
| ADL-5859 | CHEMBL494480 | Delta opioid receptor agonist | AGONIST | ChEMBL |
| AXOMADOL | CHEMBL3989680 | Delta opioid receptor agonist | AGONIST | ChEMBL |
| AZD-7268 | CHEMBL1946618 | Delta opioid receptor agonist | AGONIST | ChEMBL |
| BENZHYDROCODONE | CHEMBL3137321 | Opioid receptors; mu/kappa/delta agonist | AGONIST | ChEMBL |
| BENZHYDROCODONE HYDROCHLORIDE | CHEMBL3137310 | Opioid receptors; mu/kappa/delta agonist | AGONIST | ChEMBL |
| CEBRANOPADOL | CHEMBL2364605 | Opioid receptors; mu/kappa/delta agonist | AGONIST | ChEMBL |
| CODEINE | CHEMBL485 | Opioid receptors; mu/kappa/delta agonist | AGONIST | ChEMBL |
| CODEINE PHOSPHATE | CHEMBL6067642 | Opioid receptors; mu/kappa/delta agonist | AGONIST | ChEMBL |
1 to 10 of 30
See all 30 drugsTrials496
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07398404 | NALTREXONE | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07285473 | NALTREXONE | PHASE2 | ClinicalTrials.gov | |
| NCT07224087 | NALTREXONE | PHASE1 | ClinicalTrials.gov | |
| NCT07224009 | NALTREXONE | PHASE2 | ClinicalTrials.gov | |
| NCT07221565 | NALTREXONE | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07036029 | NALBUPHINE | PHASE1 | ClinicalTrials.gov | |
| NCT07014644 | NALTREXONE | PHASE2 | ClinicalTrials.gov | |
| NCT07008443 | NALBUPHINE | PHASE4 | ClinicalTrials.gov | |
| NCT06845124 | NALTREXONE | PHASE2 | ClinicalTrials.gov | |
| NCT06809166 | NALTREXONE | PHASE4 | ClinicalTrials.gov |
1 to 10 of 496
See all 496 trialsNIH grants971
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | OPRD1 papers | Newest fiscal year |
|---|---|---|---|
| U10AA008401 | Collaborative Study on the Genetics of Alcoholism (COGA). | 9 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 6 | 2025 |
| P50AA012870 | Center for the Translational Neuroscience of Alcoholism | 5 | 2025 |
| ZIAAA000301 | Integrative genetics of behavior with high throughput technologies | 5 | 2025 |
| R01DA008863 | Regulation Of Opioid Receptor Signaling by Endogenous Peptides | 4 | 2025 |
| ZIACP010121 | Molecular Epidemiology Studies of Occupational and Environmental Exposures | 4 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 3 | 2025 |
| R01DA012864 | Mechanisms and Cellular Function of Opioid Receptor Endocytosis | 3 | 2025 |
| UL1TR001863 | Yale Clinical and Translational Science Award | 3 | 2025 |
| DP1DA054373 | Identifying specific genetic pathway interactions for drug use and abuse through integrative omics | 2 | 2025 |
1 to 10 of 971Source NIH's project files
See all 971 nih grantsPapers1,054
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Optimizing a culture-based approach to detect intestinal carriage of carbapenem-resistant Pseudomonas aeruginosa in humans. | J Glob Antimicrob Resist | 2026 | 42697436 | PubTator, text mining | PubMed |
| Effect of dissolved versus total zinc levels on bacterial zinc-dependent meropenem co-resistance in River Tyne sediments. | Environ Pollut | 2026 | 42668131 | PubTator, text mining | PubMed |
| The Pharmacogenomics of Opioid Response in Cancer Pain: From Receptor Polymorphisms to Tumour-Mediated Interference-A Narrative-Critical Review. | Int J Mol Sci | 2026 | 42589662 | PubTator, text mining | PubMed |
| Role of genetic polymorphisms on opioid safety and efficacy in cancer pain: A systematic review and meta-analysis. | Eur J Pharmacol | 2026 | 42492880 | PubTator, text mining | PubMed |
| OPRD1 rs4654327 and Outcomes of Extended-Release Naltrexone in Alcohol Use Disorder: An Exploratory Prospective Pharmacogenetic Study. | Psychopharmacology (Berl) | 2026 | 42373990 | PubTator, text mining | PubMed |
| Characterization of antimicrobial resistance and virulence traits of clinical Pseudomonas mosselii isolates with reduced meropenem susceptibility and preserved imipenem susceptibility. | Microbiol Spectr | 2026 | 42206854 | PubTator, text mining | PubMed |
| The association between the T allele in rs204076 and treatment retention in patients receiving medication for opioid use disorder. | Sci Rep | 2026 | 42135448 | PubTator, text mining | PubMed |
| [OPRD1 gene polymorphism (rs4654327) as a potential predictor of the effectiveness of long-acting naltrexone in patients with alcohol addiction]. | Zh Nevrol Psikhiatr Im S S Korsakova | 2026 | 42133415 | PubTator, text mining | PubMed |
| Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates obtained from patients treated in a paediatric hospital in Mexico. | Sci Rep | 2026 | 42014478 | PubTator, text mining | PubMed |
| Differences in Experimental Pain Sensitivity Between Non-African and African American Healthy Individuals and Patients with Painful Chronic Pancreatitis. | J Pain Res | 2026 | 41788416 | PubTator, text mining | PubMed |
1 to 10 of 1,054
See all 1,054 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/4985
GET https://conductscience.org/api/genes/v1/4985/patents?page=2